                         SEQUENCE LISTING

<110>  Zealand Pharma A/S
 
<120>  Pharmaceutical composition of GLP-1/GLP-2 dual agonists

<130>  P121098PCT

<160>  3     

<170>  PatentIn version 3.5

<210>  1
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MOD_RES
<222>  (16)..(16)
<223>  Xaa is Lys or D-Lys in which an albumin binding moiety 
       [K([17-carboxy-heptadecanoyl]-isoGlu)] is conjugated to the 
       GLP-1/GLP-2 dual agonist

<400>  1

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  2
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 dual agonist peptide (Formula A)


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is Thr or Ser

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is Thr or Ser

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is Lys or D-Lys in which an albumin binding moiety 
       [K([17-carboxy-heptadecanoyl]-isoGlu)] is conjugated to the 
       GLP-1/GLP-2 dual agonist

<220>
<221>  MISC_FEATURE
<222>  (28)..(28)
<223>  Xaa is Gln, Glu, Ala, His, Tyr, Leu, Lys, Arg or Ser

<400>  2

His Xaa Glu Gly Xaa Phe Xaa Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Xaa His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  3
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 dual agonist peptide (Formula B)


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is Thr or Ser

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is Lys or D-Lys in which an albumin binding moiety 
       [K([17-carboxy-heptadecanoyl]-isoGlu)] is conjugated to the 
       GLP-1/GLP-2 dual agonist

<220>
<221>  MISC_FEATURE
<222>  (28)..(28)
<223>  Xaa is Gln, Glu, Ala, His, Tyr, Leu, Lys, Arg or Ser

<400>  3

His Xaa Glu Gly Xaa Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Xaa His Lys Ile Thr 
            20                  25                  30          


Asp 
    


